FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4200314750> ?p ?o ?g. }

• W4200314750 endingPage "49" @default.
• W4200314750 startingPage "49" @default.
• W4200314750 abstract "As with many other pathogens, SARS-CoV-2 cell infection is strongly dependent on the interaction of the virus-surface Spike protein with the glycosaminoglycans of target cells. The SARS-CoV-2 Spike glycoprotein was previously shown to interact with cell-surface-exposed heparan sulfate and heparin in vitro. With the aim of using Enoxaparin as a treatment for COVID-19 patients and as prophylaxis to prevent interpersonal viral transmission, we investigated GAG binding to the Spike full-length protein, as well as to its receptor binding domain (RBD) in solution by isothermal fluorescence titration. We found that Enoxaparin bound to both protein variants with similar affinities, compared to the natural GAG ligand heparan sulfate (with Kd-values in the range of 600–680 nM). Using size-defined Enoxaparin fragments, we discovered the optimum binding for dp6 or dp8 for the full-length Spike protein, whereas the RBD did not exhibit a significant chain-length-dependent affinity for heparin oligosaccharides. The soluble ACE2 receptor was found to interact with unfractionated GAGs in the low µM Kd range, but with size-defined heparins with clearly sub-µM Kd-values. Interestingly, the structural heparin analogue, pentosan polysulfate (PPS), exhibited high binding affinities to both Spike variants as well as to the ACE2 receptor. In viral infection experiments, Enoxaparin and PPS both showed a strong inhibition of infection in a concentration range of 50–500 µg/mL. Both compounds were found to retain their inhibitory effects at 500 µg/mL in a natural biomatrix-like human sputum. Our data suggest the early topical treatment of SARS-CoV-2 infections with inhaled Enoxaparin; some clinical studies in this direction are already ongoing, and they further imply an oral or nasal prophylactic inactivation of the virus by Enoxaparin or PPS for the prevention of inter-personal viral transmission." @default.
• W4200314750 created "2021-12-31" @default.
• W4200314750 creator A5024272482 @default.
• W4200314750 creator A5032058761 @default.
• W4200314750 creator A5057883288 @default.
• W4200314750 creator A5058851195 @default.
• W4200314750 creator A5078008743 @default.
• W4200314750 creator A5087909171 @default.
• W4200314750 date "2021-12-27" @default.
• W4200314750 modified "2023-09-27" @default.
• W4200314750 title "Enoxaparin and Pentosan Polysulfate Bind to the SARS-CoV-2 Spike Protein and Human ACE2 Receptor, Inhibiting Vero Cell Infection" @default.
• W4200314750 cites W1997377582 @default.
• W4200314750 cites W2026624072 @default.
• W4200314750 cites W2080299160 @default.
• W4200314750 cites W2120477137 @default.
• W4200314750 cites W2121886286 @default.
• W4200314750 cites W2138611695 @default.
• W4200314750 cites W2150561062 @default.
• W4200314750 cites W2205101660 @default.
• W4200314750 cites W2212792660 @default.
• W4200314750 cites W2514574167 @default.
• W4200314750 cites W2911305289 @default.
• W4200314750 cites W2948622157 @default.
• W4200314750 cites W3001897055 @default.
• W4200314750 cites W3007643904 @default.
• W4200314750 cites W3010441732 @default.
• W4200314750 cites W3020764391 @default.
• W4200314750 cites W3022435472 @default.
• W4200314750 cites W3080584254 @default.
• W4200314750 cites W3085153423 @default.
• W4200314750 cites W3094975056 @default.
• W4200314750 cites W3097878033 @default.
• W4200314750 cites W3104432614 @default.
• W4200314750 cites W3109609475 @default.
• W4200314750 cites W3110805913 @default.
• W4200314750 cites W3115315281 @default.
• W4200314750 cites W3119448318 @default.
• W4200314750 cites W3124760710 @default.
• W4200314750 cites W3159697887 @default.
• W4200314750 cites W3164519583 @default.
• W4200314750 cites W3168566956 @default.
• W4200314750 cites W3202150016 @default.
• W4200314750 cites W3214413850 @default.
• W4200314750 cites W4200433224 @default.
• W4200314750 doi "https://doi.org/10.3390/biomedicines10010049" @default.
• W4200314750 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/35052728" @default.
• W4200314750 hasPublicationYear "2021" @default.
• W4200314750 type Work @default.
• W4200314750 citedByCount "10" @default.
• W4200314750 countsByYear W42003147502022 @default.
• W4200314750 countsByYear W42003147502023 @default.
• W4200314750 crossrefType "journal-article" @default.
• W4200314750 hasAuthorship W4200314750A5024272482 @default.
• W4200314750 hasAuthorship W4200314750A5032058761 @default.
• W4200314750 hasAuthorship W4200314750A5057883288 @default.
• W4200314750 hasAuthorship W4200314750A5058851195 @default.
• W4200314750 hasAuthorship W4200314750A5078008743 @default.
• W4200314750 hasAuthorship W4200314750A5087909171 @default.
• W4200314750 hasBestOaLocation W42003147501 @default.
• W4200314750 hasConcept C108625454 @default.
• W4200314750 hasConcept C116569031 @default.
• W4200314750 hasConcept C140704245 @default.
• W4200314750 hasConcept C153074725 @default.
• W4200314750 hasConcept C153911025 @default.
• W4200314750 hasConcept C159047783 @default.
• W4200314750 hasConcept C170493617 @default.
• W4200314750 hasConcept C185592680 @default.
• W4200314750 hasConcept C202751555 @default.
• W4200314750 hasConcept C2522874641 @default.
• W4200314750 hasConcept C2777557582 @default.
• W4200314750 hasConcept C2778041096 @default.
• W4200314750 hasConcept C51639874 @default.
• W4200314750 hasConcept C55493867 @default.
• W4200314750 hasConcept C58475186 @default.
• W4200314750 hasConcept C86803240 @default.
• W4200314750 hasConceptScore W4200314750C108625454 @default.
• W4200314750 hasConceptScore W4200314750C116569031 @default.
• W4200314750 hasConceptScore W4200314750C140704245 @default.
• W4200314750 hasConceptScore W4200314750C153074725 @default.
• W4200314750 hasConceptScore W4200314750C153911025 @default.
• W4200314750 hasConceptScore W4200314750C159047783 @default.
• W4200314750 hasConceptScore W4200314750C170493617 @default.
• W4200314750 hasConceptScore W4200314750C185592680 @default.
• W4200314750 hasConceptScore W4200314750C202751555 @default.
• W4200314750 hasConceptScore W4200314750C2522874641 @default.
• W4200314750 hasConceptScore W4200314750C2777557582 @default.
• W4200314750 hasConceptScore W4200314750C2778041096 @default.
• W4200314750 hasConceptScore W4200314750C51639874 @default.
• W4200314750 hasConceptScore W4200314750C55493867 @default.
• W4200314750 hasConceptScore W4200314750C58475186 @default.
• W4200314750 hasConceptScore W4200314750C86803240 @default.
• W4200314750 hasIssue "1" @default.
• W4200314750 hasLocation W42003147501 @default.
• W4200314750 hasLocation W42003147502 @default.
• W4200314750 hasLocation W42003147503 @default.
• W4200314750 hasLocation W42003147504 @default.
• W4200314750 hasOpenAccess W4200314750 @default.
• W4200314750 hasPrimaryLocation W42003147501 @default.

• next